

21st March, 2026

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Torrent Pharma launches oral and injectable formulations of Semaglutide

A press release issued by the Company with respect to captioned subject is attached for your information and record.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN TRIVEDI
COMPANY SECRETARY

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

Regd. Office: Avirat, Thaltej Shilaj Road, Ahmedabad – 380059

Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com

MEDIA RELEASE

Torrent Pharma launches oral and injectable formulations of Semaglutide

First company in India to launch generic oral semaglutide; injectable launched with a starting price
Rs. 3,999 per month

Saturday March 21, 2026: Torrent Pharmaceuticals today announced the launch of its Semaglutide brands - Sembolic and Semalix - in India, in both oral and injectable formulations. The launch expands the company's presence in metabolic disorders such as type-2 diabetes and obesity.

Commenting on the launch, Amal Kelshikar, CEO – India Business, Torrent Pharma, said: “Metabolic disorders represent one of the most significant healthcare challenges in India with a significant portion of our population affected by Type-2 Diabetes. Our entry into the GLP-1 therapy segment reflects Torrent’s commitment to expanding treatment options available to healthcare professionals managing complex metabolic conditions at affordable prices. We are proud to be the first Indian company to offer this treatment across oral and injectable formulations, giving healthcare professionals a holistic choice for treating patients”

About GLP-1 Drug Category

GLP-1 (glucagon-like peptide-1) receptor agonists are well-established prescription medications for the management of type 2 diabetes and obesity. They work by enhancing insulin secretion, reducing glucagon levels and help regulate appetite. They have been shown to be effective at decreasing haemoglobin A1c (HbA1c), promoting weight loss and reducing the risk of cardiovascular events by mimicking the hormone GLP-1.

About Torrent Pharmaceuticals Limited

Torrent Pharma, with annual revenues of more than Rs 11,500 crores, is the flagship Company of the Torrent Group, with group revenues of ~Rs 45,000 crores. Post JB Pharma acquisition it is ranked 5th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), Pain Management and Cosmo-Dermatology.

It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 750+ scientists.

In case of any enquiry / clarification,
please contact Mr. Jayesh Desai on +91 9824501396

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126
Regd. Office: Avirat, Thaltej Shilaj Road, Ahmedabad - 380059
Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com